Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 2 study of extended-release interferon alfa-2b versus peginterferon alfa-2b plus ribavirin in chronic hepatitis C genotype 1
2009-015121-37Phase 2Completed
- Sponsor
- ANRS
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa-2b, peginterferon alfa-2b and ribavirin in hepatitis C virus infection (3 arms), sponsored by ANRS. Primary endpoints: Change in viral load at week 4, Change in viral load at week 12 and 1 more. Started Oct 2009; status: completed.
02
Drugs
interferon alfa-2bpeginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-015121-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015121-37.